Abstract
Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
CNS & Neurological Disorders - Drug Targets
Title:Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
Volume: 14 Issue: 4
Author(s): Alwin Poot-Ake, Stephanie Mijangos-Moreno, Danielle Manjarrez-Martin, Ramses Jimenez-Moreno, Pedro R. Aquino-Hernandez, Elda Pacheco-Pantoja, Oscar Arias-Carrion, Andrea Sarro-Ramirez, Gloria Arankowsky-Sandoval and Eric Murillo-Rodriguez
Affiliation:
Keywords: Dopamine, hypothalamus, modafinil, narcolepsy, protein, pons, rat, wakefulness, western blot.
Abstract: Modafinil (MOD) it has to be considered as a wake-inducing drug to treat sleep disorders such as excessive sleepiness in narcolepsy, shift-work disorder, and obstructive/sleep apnea syndrome. Current evidence suggests that MOD induces waking involving the dopamine D1 receptor. However, little is known regarding the molecular elements linked in the wake-promoting actions of MOD. Since the D1 receptor activates the mitogen-activated protein kinase (MAP-K) cascade, it raises the interesting possibility that effects of MOD would depend upon the activation of MAP-K. Here we tested the expression of MAP-K in hypothalamus as well as pons after the microinjection of MOD (10 or 20μg/1μL) in rats into anterior hypothalamus, a wake-inducing brain area. Intrahypothalamic injections of MOD promoted MAP-K phosphorylation in hypothalamus and pons. Taken together, these results suggest that the wake-inducing compound MOD promotes the MAP-K phosphorylation.
Export Options
About this article
Cite this article as:
Poot-Ake Alwin, Mijangos-Moreno Stephanie, Manjarrez-Martin Danielle, Jimenez-Moreno Ramses, Aquino-Hernandez R. Pedro, Pacheco-Pantoja Elda, Arias-Carrion Oscar, Sarro-Ramirez Andrea, Arankowsky-Sandoval Gloria and Murillo-Rodriguez Eric, Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429113609
DOI https://dx.doi.org/10.2174/1871527314666150429113609 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (A Significant Step Towards New Altitude)
Current Molecular Medicine Activation of Human Platelets by 2-Arachidonoylglycerol: Role of PKC in NO/cGMP Pathway Modulation
Current Neurovascular Research Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Palmitoylated Prolactin-releasing Peptide Reduced Aβ Plaques and Microgliosis in the Cerebellum: APP/PS1 Mice Study
Current Alzheimer Research Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Experimental Approaches to Tse Prevention Via Inhibition of Prion Formation
Protein & Peptide Letters Inhibition of Angiogenesis as a Treatment Strategy for Neuroblastoma
Current Cancer Therapy Reviews Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Effects of Nonsteroidal Anti-inflammatory Drugs on Neurodegenerative Diseases
Current Pharmaceutical Design Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Chemotherapy In Japanese Encephalitis: Are We There Yet?
Infectious Disorders - Drug Targets